Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet

Stock News

2025/10/24

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. ("Shon Pharmaceutical"), has received a "Notice of Drug Supplement Application Approval" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1127558805"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127558805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127558805?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127558805","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-24 15:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白馬股","start_time":0,"source_url":"","article_id":"1127558805","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127558805","pubTimestamp":1761291737,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0175":"白马股","BK0012":"证金概念","BK0187":"一线龙头","BK0196":"行业龙头","BK0184":"上海国资改革","02607":"上海医药","BK0028":"国家队","BK0209":"零售","BK0097":"医药电商","BK0099":"上海本地重组","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"上海医药控股股份有限公司（601607.SH）子公司成为氨磺必利口服分散片上市许可持有人","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shon Pharmaceutical Co., Ltd. (\"Shon Pharmaceutical\"), has received a \"Notice of Drug Supplement Application Approval\" from the National Medical Products Administration, which allows the change of上市 license holder for Amasulpiride Oral Dispersible Tablet to Shanghai Shon Pharmaceutical Co., Ltd. The announcement states that Amasulpiride Oral Dispersible Tablet is an improved dosage form of Amasulpiride, which was launched by Sanofi in France in 1986, and is used for treating adult schizophrenia. In September 2025, Shon Pharmaceutical submitted a registration application for the change of the drug's上市 license holder to the National Medical Products Administration, which has been accepted.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}